Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis Following Anti-CD19 CAR-T Cell Therapy

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2023 Jan 20

PMID 36661736

Authors

Lea Naomi Eder

Danilo Martinovic

Paolo Mazzeo

Christina Ganster

Justin Hasenkamp

Julia Thomson

Arne Trummer

Detlef Haase

Gerald Wulf

Affiliations

Soon will be listed here.

Abstract

We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small -mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the -mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype. This case may serve as a paradigmatic example of clonal hematopoietic progression in a patient undergoing CAR-T cell therapy, especially in the context of a -mutated clone.

Citing Articles

From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.

Ahmadi S, Rahimian E, Rahimi S, Zarandi B, Bahraini M, Soleymani M Biomark Res. 2024; 12(1):137.

PMID: 39538363 PMC: 11565275. DOI: 10.1186/s40364-024-00676-9.

CAR-T Cell Therapy in Large B Cell Lymphoma.

Testa U, Leone G, Pelosi E, Castelli G, Hohaus S Mediterr J Hematol Infect Dis. 2023; 15(1):e2023066.

PMID: 38028399 PMC: 10631715. DOI: 10.4084/MJHID.2023.066.

TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia.

Testa U, Castelli G, Pelosi E Mediterr J Hematol Infect Dis. 2023; 15(1):e2023038.

PMID: 37435040 PMC: 10332352. DOI: 10.4084/MJHID.2023.038.

Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface.

Buttigieg M, Rauh M JCO Precis Oncol. 2023; 7:e2300132.

PMID: 37343201 PMC: 10309572. DOI: 10.1200/PO.23.00132.

References

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Come C, Balhuizen A, Bonnet D, Porse B . Myelodysplastic syndrome patient-derived xenografts: from no options to many. Haematologica. 2020; 105(4):864-869. PMC: 7109759. DOI: 10.3324/haematol.2019.233320. View

Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

Fried S, Avigdor A, Bielorai B, Meir A, Besser M, Schachter J . Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019; 54(10):1643-1650. DOI: 10.1038/s41409-019-0487-3. View

Miller P, Sperling A, Brea E, Leick M, Fell G, Jan M . Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021; 5(15):2982-2986. PMC: 8361461. DOI: 10.1182/bloodadvances.2021004554. View

Yan B, Wang H, Rabbani Z, Zhao Y, Li W, Yuan Y . Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. Cancer Res. 2006; 66(24):11565-70. DOI: 10.1158/0008-5472.CAN-06-2540. View

Strati P, Varma A, Adkins S, Nastoupil L, Westin J, Hagemeister F . Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2020; 106(10):2667-2672. PMC: 8485681. DOI: 10.3324/haematol.2020.254045. View

Locke F, Ghobadi A, Jacobson C, Miklos D, Lekakis L, Oluwole O . Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2018; 20(1):31-42. PMC: 6733402. DOI: 10.1016/S1470-2045(18)30864-7. View

Schubert M, Schmitt M, Wang L, Ramos C, Jordan K, Muller-Tidow C . Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2020; 32(1):34-48. DOI: 10.1016/j.annonc.2020.10.478. View

10.

Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz J, Purdon T . Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020; 4(15):3776-3787. PMC: 7422135. DOI: 10.1182/bloodadvances.2020002509. View

11.

Uslu U, June C . CAR T-cell Therapy Meets Clonal Hematopoiesis. Blood Cancer Discov. 2022; 3(5):382-384. PMC: 9445765. DOI: 10.1158/2643-3230.BCD-22-0067. View

12.

Saini N, Swoboda D, Greenbaum U, Ma J, Patel R, Devashish K . Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discov. 2022; 3(5):385-393. PMC: 9445749. DOI: 10.1158/2643-3230.BCD-21-0177. View

13.

Taneja A, Jain T . CAR-T-OPENIA: Chimeric antigen receptor T-cell therapy-associated cytopenias. EJHaem. 2022; 3(Suppl 1):32-38. PMC: 9175816. DOI: 10.1002/jha2.350. View

14.

Teipel R, Kroschinsky F, Kramer M, Kretschmann T, Egger-Heidrich K, Kruger T . Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Adv. 2022; 6(6):1941-1946. PMC: 8941459. DOI: 10.1182/bloodadvances.2021005747. View

15.

Hansen D, Dam M, Faramand R . Toxicities associated with adoptive cellular therapies. Best Pract Res Clin Haematol. 2021; 34(3):101287. DOI: 10.1016/j.beha.2021.101287. View

16.

Martin R, Acha P, Ganster C, Palomo L, Dierks S, Fuster-Tormo F . Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes. Am J Hematol. 2018; 93(6):E152-E154. PMC: 6001632. DOI: 10.1002/ajh.25089. View

17.

Sharma N, Reagan P, Liesveld J . Cytopenia after CAR-T Cell Therapy-A Brief Review of a Complex Problem. Cancers (Basel). 2022; 14(6). PMC: 8946106. DOI: 10.3390/cancers14061501. View

18.

Cordeiro A, Bezerra E, Hirayama A, Hill J, Wu Q, Voutsinas J . Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. Biol Blood Marrow Transplant. 2019; 26(1):26-33. PMC: 6953906. DOI: 10.1016/j.bbmt.2019.08.003. View

19.

Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman P, Mar B . Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26):2488-98. PMC: 4306669. DOI: 10.1056/NEJMoa1408617. View

20.

Bernard E, Nannya Y, Hasserjian R, Devlin S, Tuechler H, Medina-Martinez J . Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020; 26(10):1549-1556. PMC: 8381722. DOI: 10.1038/s41591-020-1008-z. View